These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2279212)

  • 21. A pilot study of a Neuro-Stimulator Device vs. methadone in alleviating opiate withdrawal symptoms.
    Elmoghazy E; Johnson BD; Alling FA
    NIDA Res Monogr; 1989; 95():388-9. PubMed ID: 2701306
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nasal administration of naloxone for detection of opiate dependence.
    Loimer N; Hofmann P; Chaudhry HR
    J Psychiatr Res; 1992 Jan; 26(1):39-43. PubMed ID: 1560408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program--a randomized, double blind, placebo controlled, prospective study.
    Herman I; Shamir D; Bar-Hamburger R; Pick CG; Schreiber S
    Addict Behav; 2005 Jul; 30(6):1154-67. PubMed ID: 15925125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid opiate detoxification with clonidine and naloxone.
    Riordan CE; Kleber HD
    Lancet; 1980 May; 1(8177):1079-80. PubMed ID: 6103408
    [No Abstract]   [Full Text] [Related]  

  • 28. How should opiate withdrawal be measured?
    Turkington D; Drummond DC
    Drug Alcohol Depend; 1989 Oct; 24(2):151-3. PubMed ID: 2676443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria.
    Kosten TA; Jacobsen LK; Kosten TR
    Am J Drug Alcohol Abuse; 1989; 15(3):237-50. PubMed ID: 2763981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cocaine attenuates opiate withdrawal in human and rat.
    Kosten TA
    NIDA Res Monogr; 1989; 95():361-2. PubMed ID: 2640996
    [No Abstract]   [Full Text] [Related]  

  • 31. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal.
    Rosen MI; McMahon TJ; Woods SW; Pearsall HR; Kosten TR
    Eur J Pharmacol; 1996 Jul; 307(3):251-7. PubMed ID: 8836612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonist treatment of opioid withdrawal translational low dose approach.
    Mannelli P; Gottheil E; Van Bockstaele EJ
    J Addict Dis; 2006; 25(2):1-8. PubMed ID: 16785213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
    Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
    Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of gamma-hydroxybutyric acid on naloxone-precipitated opiate withdrawal.
    Rosen MI; Pearsall HR; Woods SW; Kosten TR
    Neuropsychopharmacology; 1996 Mar; 14(3):187-93. PubMed ID: 8866702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two new rating scales for opiate withdrawal.
    Handelsman L; Cochrane KJ; Aronson MJ; Ness R; Rubinstein KJ; Kanof PD
    Am J Drug Alcohol Abuse; 1987; 13(3):293-308. PubMed ID: 3687892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ultra-rapid opiate detoxification on withdrawal syndrome.
    Safari F; Mottaghi K; Malek S; Salimi A
    J Addict Dis; 2010 Oct; 29(4):449-54. PubMed ID: 20924880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
    Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
    Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Jan; 248(1):127-34. PubMed ID: 2913267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol.
    Frederickson RC; Hewes CR; Aiken JW
    J Pharmacol Exp Ther; 1976 Nov; 199(2):375-84. PubMed ID: 988178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.